These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

634 related articles for article (PubMed ID: 18631950)

  • 1. Behavioral effects of current Alzheimer's disease treatments: a descriptive review.
    Cummings JL; Mackell J; Kaufer D
    Alzheimers Dement; 2008 Jan; 4(1):49-60. PubMed ID: 18631950
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment strategies for the behavioral symptoms of Alzheimer's disease: focus on early pharmacologic intervention.
    Beier MT
    Pharmacotherapy; 2007 Mar; 27(3):399-411. PubMed ID: 17316151
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Contemporary issues in the treatment of Alzheimer's disease: tangible benefits of current therapies.
    Tariot PN
    J Clin Psychiatry; 2006; 67 Suppl 3():15-22; quiz 23. PubMed ID: 16649847
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Memantine therapy of behavioral symptoms in community-dwelling patients with moderate to severe Alzheimer's disease.
    Grossberg GT; Pejović V; Miller ML; Graham SM
    Dement Geriatr Cogn Disord; 2009; 27(2):164-72. PubMed ID: 19194105
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improvement in behavioural symptoms in patients with moderate to severe Alzheimer's disease by memantine: a pooled data analysis.
    Gauthier S; Loft H; Cummings J
    Int J Geriatr Psychiatry; 2008 May; 23(5):537-45. PubMed ID: 18058838
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of memantine on behavioral and psychological symptoms related to dementia: a systematic meta-analysis.
    Maidment ID; Fox CG; Boustani M; Rodriguez J; Brown RC; Katona CL
    Ann Pharmacother; 2008 Jan; 42(1):32-8. PubMed ID: 18056833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of memantine on behavioural symptoms in Alzheimer's disease patients: an analysis of the Neuropsychiatric Inventory (NPI) data of two randomised, controlled studies.
    Gauthier S; Wirth Y; Möbius HJ
    Int J Geriatr Psychiatry; 2005 May; 20(5):459-64. PubMed ID: 15852444
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Domain-specific improvement of cognition on memantine in patients with Alzheimer's disease treated with rivastigmine.
    Riepe MW; Adler G; Ibach B; Weinkauf B; Tracik F; Gunay I
    Dement Geriatr Cogn Disord; 2007; 23(5):301-6. PubMed ID: 17356273
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of open-label donepezil treatment in patients with Alzheimer's disease discontinuing memantine monotherapy.
    Sakka P; Tsolaki M; Hort J; Hager K; Soininen H; López Pousa S; Li C; Schwam E
    Curr Med Res Opin; 2007 Dec; 23(12):3153-65. PubMed ID: 17988434
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential effects of current specific treatments on behavioral and psychological symptoms in patients with Alzheimer's disease: a 12-month, randomized, open-label trial.
    Cumbo E; Ligori LD
    J Alzheimers Dis; 2014; 39(3):477-85. PubMed ID: 24164733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Memantine treatment of cognitive symptoms in mild to moderate Alzheimer disease: secondary analyses from a placebo-controlled randomized trial.
    Pomara N; Ott BR; Peskind E; Resnick EM
    Alzheimer Dis Assoc Disord; 2007; 21(1):60-4. PubMed ID: 17334274
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of the effect of memantine in reducing the worsening of clinical symptoms in patients with moderate to severe Alzheimer's disease.
    Wilkinson D; Andersen HF
    Dement Geriatr Cogn Disord; 2007; 24(2):138-45. PubMed ID: 17622761
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Efficacy of memantine in the treatment of Alzheimer's disease].
    Molinuevo Guix JL; Lladó Plarrumaní A
    Neurologia; 2005 Dec; 20(10):686-91. PubMed ID: 16317590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The place of memantine in the treatment of Alzheimer's disease: a number needed to treat analysis.
    Livingston G; Katona C
    Int J Geriatr Psychiatry; 2004 Oct; 19(10):919-25. PubMed ID: 15449303
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The expert consensus guideline series. Treatment of dementia and its behavioral disturbances. Introduction: methods, commentary, and summary.
    Alexopoulos GS; Jeste DV; Chung H; Carpenter D; Ross R; Docherty JP
    Postgrad Med; 2005 Jan; Spec No():6-22. PubMed ID: 17203561
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The efficacy and safety of risperidone in the treatment of psychosis of Alzheimer's disease and mixed dementia: a meta-analysis of 4 placebo-controlled clinical trials.
    Katz I; de Deyn PP; Mintzer J; Greenspan A; Zhu Y; Brodaty H
    Int J Geriatr Psychiatry; 2007 May; 22(5):475-84. PubMed ID: 17471598
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Drug therapy for Alzheimer's disease].
    Shoji M
    Brain Nerve; 2010 Jul; 62(7):777-85. PubMed ID: 20675882
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of rivastigmine in the treatment of behavioral disturbances associated with dementia: review of neuropsychiatric impairment in Alzheimer's disease.
    Grossberg GT
    Curr Med Res Opin; 2005 Oct; 21(10):1631-9. PubMed ID: 16238903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sex influences on cholinesterase inhibitor treatment in elderly individuals with Alzheimer's disease.
    Haywood WM; Mukaetova-Ladinska EB
    Am J Geriatr Pharmacother; 2006 Sep; 4(3):273-86. PubMed ID: 17062329
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The action of memantine on the cognitive disorders of patients with dementia: reflections following two years' experience in Spain].
    Robles-Bayón A
    Rev Neurol; 2006 Mar 1-15; 42(5):288-96. PubMed ID: 16538592
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.